Galera Therapeutics, Inc.
Calidad de datos: 83%
GRTX
OTC
Manufacturing
Chemicals
$0.04
$0.00
(0.00%)
Cap. Mercado: 3.09 M
Precio
$0.04
Cap. Mercado
3.09 M
Rango del Día
$0.04 — $0.04
Rango de 52 Semanas
$0.02 — $0.06
Volumen
1,005
Apertura $0.04
Promedio 50D / 200D
$0.04
15.49% above
Promedio 50D / 200D
$0.03
57.69% above
Quick Summary
Puntos Clave
Negative free cash flow of -6.05 M
P/E of 0.02 — trading at a low valuation
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
N/A
ROIC-50.31%
Net MarginN/A
Op. MarginN/A
Seguridad
Debt / Equity
N/A
Current Ratio8.20
Interest CoverageN/A
Valoración
PE (TTM)
0.02
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 0.0 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | 149.05 M |
| ROE | N/A | ROA | 2697.72% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6.05 M |
| ROIC | -50.31% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 8.20 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 4.30 M | Tangible Book Value | -149.22 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 0.02 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -195.51% | ||
| Market Cap | 3.09 M | Enterprise Value | -1.38 M |
| Per Share | |||
| EPS (Diluted TTM) | 0.64 | Revenue / Share | N/A |
| FCF / Share | -0.08 | OCF / Share | -0.08 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -4.06% |
| SBC-Adj. FCF | -6.92 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | 149.05 M | -18.96 M | -59.08 M | -62.22 M | -80.53 M |
| EPS (Diluted) | 0.64 | -0.34 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -2.54 M | -20.16 M | -49.26 M | -51.23 M | -73.37 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 349,000.0 | 3.15 M | 24.12 M | 31.01 M | 52.42 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 0.0 | 20,000.0 | 259,000.0 | 114,000.0 | 778,000.0 |
| Interest Expense | 0.0 | 0.0 | 11.41 M | 11.57 M | 7.19 M |
| Income Tax | 0.0 | -203,000.0 | 0.0 | 70,000.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7.20 M | 10.10 M | 26.14 M | 44.04 M | 83.31 M |
| Total Liabilities | 645,000.0 | 153.77 M | 157.33 M | 153.22 M | 141.32 M |
| Shareholders' Equity | 3.97 M | -148.04 M | -131.19 M | -109.18 M | -58.00 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 6.38 M | 8.29 M | 18.26 M | 4.27 M | 19.86 M |
| Current Assets | 7.10 M | 10.00 M | 21.63 M | 38.54 M | 77.39 M |
| Current Liabilities | 645,000.0 | 1.67 M | 4.96 M | 13.38 M | 12.94 M |
{"event":"ticker_viewed","properties":{"ticker":"GRTX","listing_kind":"stock","pathname":"/stocks/grtx","exchange":"OTC","country":"US"}}